Rankings

Market Cap
Revenue
Operating Income
CapEx
Total Assets
Net Assets
Cash on Hand

Sectors

Technology
Healthcare
Financial Services
Consumer Cyclical
Communication Services
Industrials
Consumer Defensive
Energy
Basic Materials
Real Estate
Utilities

Pages

Home
Earnings Calendar
All Sectors
Terms
Privacy

© 2026 Market Cap Arena. All rights reserved.v1.2.29

KYMRKymera Therapeutics, Inc.

$7B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

$2M100.0% margin

Operating Income

-$12M-642.8% margin

Net Income

-$12M-628.1% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+92.9%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$297,000

Balance Sheet

Total Assets

$117M

Total Liabilities

$191M

Stockholders' Equity

-$74M

Cash & Equivalents

$76M

← FY 2019 All Quarters Q1 2020 →

KYMR Q4 2019 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena